Morning Briefing Podcast: Pharma: Shareholders Hail Moderna's Cancer Study Success
Moderna and Merck are pleasing not only patients with good results from a cancer vaccine - but also their shareholders. Moderna's stock jumped by 176 percent yesterday. Also, because this is about more than just a vaccine.
We haven't written up this one. Handelsblatt has the full story — the link below goes straight to it.